![]() |
![]() ![]() ![]() |
||||
![]() |
Mariana Kaplan,
M.D.
The Kaplan Laboratory is studying the mechanisms by which premature vascular damage occurs in SLE. We have described that lupus patients show evidence of increased endothelial cell apoptosis, which correlates with tissue factor generation and vasomotor dysfunction, a predictor of future development of atherosclerosis. We have also found that patients with lupus have impaired vascular repair and that this phenomenon is mediated by type I Interferons. The Kaplan Laboratory is currently characterizing the molecular pathways by which type I Interferons promote vascular damage and interfere with vascular repair in lupus, using human and murine models. Current pathways investigated include the inflammasome as well as PPAR-gamma. Another area of interest of this laboratory is how innate immunity mediates the development of organ damage in lupus and, potentially, in other autoimmune diseases. We have recently characterized an abnormal neutrophil subset that appears to be pathogenic in lupus, synthesizes type I interferons, promotes vascular damage, and interferes with vascular repair. We are currently characterizing the mechanisms that drive the abnormal phenotype and function of these cells and their role in autoantigen exposure and stimulation of innate and adaptive immunity. Recently, we have described that the formation of neutrophil extracellular traps (NETS) is enhanced in low density granulocytes from SLE patients and that this phenomenon is associated to vascular damage, autoantibody production and type I IFN synthesis. Current work is focusing on establish the pathways leading to enhanced NET formation in SLE as well as the in vivo implications that this phenomenon has in lupus pathogenesis. In addition, the Kaplan Laboratory is examining mechanisms of tissue damage in SLE and whether specific pharmacologic interventions can abrogate/ameliorate these complications in lupus and, potentially, in other autoimmune diseases.
Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. Journal of Immunology 2011; 187(1):538-52. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT. Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis. Journal of Immunology 2011; 187(1):490-500. Marder W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S, Brook R, Kaplan MJ. Interleukin-17 as a novel predictor of vascular function in rheumatoid arthritis. Annals of Rheumatic Diseases 2011; July 4th (epublished ahead of print). Kahlenberg JM and Kaplan MJ. The interplay of inflammation and cardiovascular disease in lupus. Arthritis Research & Therapy 2011; 13:203. PMID 21371346. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, and Kaplan MJ. The detrimental effects of interferon-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. Journal of Immunology 2010; 185:4457-69. PMID 20805419. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, McCune WJ, and Kaplan MJ. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I Interferons. Journal of Immunology 2010; 184:3824-97. PMID 20164424. Thacker SG, Duquaine D, Park J, and Kaplan MJ. Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus 2010; 19:288-99. PMID 20068018. Zhao W, Thacker SG, Hodgin JB, Zhang H, Wang JH, Park JL, Randolph A, Somers EC, Pennathur S, Kretzler M, Brosius FC, and Kaplan MJ. The PPAR-gamma agonist pioglitazone improves cardiometabolic risk in systemic lupus erythematosus. Journal of Immunology 2009; 183:2729-40. PMID 19620300. Monrad S, Rea KM, Thacker S, Kaplan MJ. Myeloid dendritic cells display downregulation of C-type lectin receptors and aberrant lectin in systemic lupus erythematosus. Arthritis Research & Therapy 2008; 10:R114. PMID 18811944. Monrad SU, Killen P, Anderson M, Bradke A, and Kaplan MJ. The role of aldosterone blockade in murine lupus nephritis. Arthritis Research and Therapy 2008; 10:R5. PMID 18197980. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, McCune WJ, and Kaplan MJ. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007; 110:2907-15. PMID 17638846. Ding D, Mehta H, McCune WJ, and Kaplan MJ. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. Journal of Immunology 2006; 177:5878-89. PMID 17056512. Denny M, Chandaroy P , Killen P, Caricchio R, Lewis E, Richardson B, Lee KD, Gavalchin J, and Kaplan MJ. Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. Journal of Immunology 2006; 176:2095-104. PMID 16455965. Rajagopalan S, Somers EC, Brook R, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune WJ, and Kaplan MJ. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity.
|
|
About Us | Research Opportunities | Faculty | Graduate Students | Admissions | Coursework | Immunology Seminars | Life in A2 UM Gateway | UM Medical School | Program in Biological Sciences | UM Health System Web Design by BMC Media Copyright © 2002 The Regents of the University of Michigan |